Clinical Trial Update: Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

View source ↗

Summary

Post-marketing surveillance update reporting completion of a use-results study of Esperoct (turoctocog alfa pegol) in patients with Haemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Esperoct (turoctocog alfa pegol)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Haemophilia A | Status: COMPLETED